Introduction
A large inter-dependence exists between neural circuit activity, the cerebrovascular supply supporting circuit function and synaptic/axonal microstructure, which act in concert to determine systemic sensorimotor and cognitive outcomes. Traumatic brain injury (TBI) pathology is broad, affecting multiple cellular types and hence different neurophysiological variables 1 . TBI leads to an energy metabolic decline in pediatric patients and developmental preclinical models of injury, [2] [3] [4] [5] [6] [7] consequently affecting downstream function in various cellular compartments. 1 Hence mitochondria, the subcellular organelles responsible for oxidative energy metabolism, and enriched in diverse cell types of the brain are effective targets for TBI treatments. It can be hypothesized that treatments targeting mitochondria can promote diverse cell-type specific downstream repair mechanisms in neurons, glia, vascular smooth muscle and endothelium, which can synergistically improve neurophysiological outcomes. Since energy metabolism is upstream to various cellular processes during recovery from TBI, treatments maintaining mitochondrial ion homeostasis, and hence their energy metabolic capacity, may differentially impact injury prognosis depending on the mitochondrial properties of each brain compartment.
Preservation of energy metabolism in the developing brain is not only crucial for efficient post-TBI repair via downstream energy-dependent mechanisms, but also to sustain normal ongoing developmental changes. Since cerebral vasculature, neural and axonal/synaptic microstructures dynamically change during development, [8] [9] [10] [11] [12] TBI in children are more devastating due to impediments of ongoing normal development. Given the temporally variable characteristics of TBI pathology 1 , preclinical experiments reporting on multiple biomarkers of brain function during development, preferably in a simultaneous manner and translatable to humans are necessary. Addressing this gap, our previous study utilized magnetic resonance imaging (MRI) based functional MRI (fMRI) and diffusion tensor imaging (DTI) modalities to simultaneously determine brain structural and functional changes at adolescence after TBI using the development rat model. 13 The multimodal MRI biomarkers obtained at the adolescent stage strongly correlated with the metabolic decline, reduced neural viability and behavioral debilitation observed during the Downloaded by Uc Riverside Libraries University of California Riverside from www.liebertpub.com at 12/19/19. For personal use only.
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Kaempferol treatment after TBI during early development mitigates brain parenchymal microstructure and neural functional connectivity deterioration at adolescence (DOI: 10.1089/neu.2019.6486) This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. early acute/subacute stage (0-72 hours) after TBI. 2 Acutely targeting mitochondrial ion homeostasis using Kaempferol, a pharmacological enhancer of mitochondrial Ca 2+ uniporter channel (mCU) activity and hence mitochondrial Ca 2+ cycling 14, 15 , mitigated the TBI-induced early energy metabolic decline and improved behavioral performance. 16 The early-window Kaempferol treatment regimen (1mg/Kg i.p) at 1, 24 and 48 hrs post-TBI, also improved prognosis at adolescence revealed by better stimulus-induced neurovascular coupling responses and sensorimotor behavior 17 .
Using a translatable experimental design and clinically relevant imaging markers, the present study tested the hypothesis that Kaempferol-mediated effects on the brain are diverse, through its variable effects on mitochondria in different cellular types. Rats (age; P31) underwent a fluid percussion TBI in the mild to moderate intensity and randomly assigned to vehicle or Kaempferol (1mg/Kg) groups, where treatments were made at 1, 24 and 48 hours after injury. Using fMRI and DTI measures at adolescence (2 months after injury), various system level biomarkers informing on the neural, vascular and synaptic/axonal compartments were determined to assess TBI prognosis and the effects of Kaempferol treatment.
Materials and Methods

Animals and treatment
Male Sprague-Dawley rats (n=16; 23-24 days old; weighing 60-80g) were procured from Charles River Laboratories, Wilmington, MA, USA and housed in pairs under controlled conditions. All experimental on animals were carried out in accordance with the protocol approved by a local Institutional Animal Care and Use Committee (IACUC) of
Rutgers Biomedical and Health Sciences-New Jersey Medical School and Yale University
School of Medicine. Kaempferol used in the current study was of commercial grade (Signa-Aldrich, USA) and freshly prepared into working solution using sterile saline. Routes of administration for vehicle (10% dimethyl sulfoxide in saline) and Kaempferol were through intraperitoneal injection.
Lateral fluid-percussion injury
Rats (age; P31) were subject to lateral fluid percussion injury (FPI) as previously described. 18 
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years of human age, 20 The FPI method produced diffuse moderate TBI, very similar to that observed in humans. Briefly, animals were anesthetized with Ketamine (80mg/kg i.p)-Xylazine (10mg/kg i.p) and positioned on a stereotaxic frame after confirming surgical plane anesthesia. A 3mm craniotomy was performed on the left side of the skull -5 mm posterior to the bregma and 3 mm lateral to the sagittal suture while retaining the dura. A Luer-Lock syringe hub was attached surrounding the exposed dura using cyanoacrylate adhesive. 24 hours after the Luer Lock placement, TBI was induced by attaching the Luer- 
Anatomical MRI:
MRI scanning was performed on a modified 9.4T system with Bruker spectrometer and custom built 1 Resting state and cerebrovascular reactivity fMRI:
Resting state and cerebrovascular reactivity fMRI were performed using the gradient echo (GE) echo planar imaging (EPI) sequence (TR/TE= 1000/15 ms, preceded by 8 dummy scans) using the same geometry as diffusion scans (64 x 48 matrix, 500 x 500 µm in-plane resolution) with the GE-EPI sequence producing image contrast sensitive to blood oxygenation changes (BOLD). 22 Resting-state fMRI paradigm consisted of a 5 min scan (300 repetitions), acquired in four experimental trials per animal. Cerebrovascular reactivity fMRI scans were obtained using similar GE-EPI parameters as the resting state fMRI which lasted for 12 minutes (720 repetitions). A 10% carbon dioxide gas (CO 2 ) added to the breathing gas mixture of O 2 and N 2 O (30/70%) between minutes 3 and 6 of the acquisition and repeated twice per animal.
Data analysis and statistics:
All EPI images were linearly registered to the subject's native anatomical space before further processing. BioImage Suite software (http://bioimagesuite.yale.edu/) was used for the tensor model fitting on a voxel-wise basis using the diffusion sensitive images.
Parametric maps of fractional anisotropy (FA) and mean diffusivity (MD) value maps were 
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obtain as described in our earlier studies. 23 Blood oxygen level dependent (BOLD) fMRI temporal EPI data sets obtained during the resting state and CO 2 challenge experiments were analyzed using the AFNI software. 24 EPIs were corrected for slice-time using 3dTshift
and motion using 3dvolreg with the 5 th sub-brick as the base. EPIs were subsequently spatially smoothed using a Gaussian filter (FWHM = 1.5 mm) and linearly detrended to remove temporal signal drifts for resting-state scans only. No detrending was performed on the CO 2 scans to avoid biasing the BOLD response curve to the single event CO 2 challenge. Our previous quality control scans with the same sequence showed no significant linear drift within 12 minutes the typical length of one CO 2 challenge acquisition. Parametric maps of CO 2 challenge-induced cerebrovascular reactivity were generated from a voxel-level linear model based on the "ON" and "OFF" timing of CO 2 gas delivery and expressed as the t-statistical value of the contrast between baseline (Frames 1 to 180) and CO 2 challenge (Frames 210 to 360).
For resting-state functional connectivity (RSFC) analysis, preprocessed EPIs were band pass filtered (0.01 to 0.15 Hz). Six seed voxels were chosen from each region of interest (ROI) from the right hemisphere (contralateral to the injury). The ROIs were somatosensory cortex, hippocampus and thalamic regions ensuring that the seed voxels randomly identified always lie within these respective ROIs identified using the rat brain atlas. 25 Signal time series from each selected seed voxel was cross correlated with the entire brain, producing 6 cross-correlation maps for each experimental trial. As demonstrated in our earlier studies in normal 26 and TBI animals, 13 the average RSFC map obtained from the six different cross-correlation maps represented a more accurate topology of the RSFC network. In a similar manner, the 6 correlation maps obtained using 6 random seed voxels within each respective ROI (somatosensory cortical, hippocampus and thalamus) were obtained for each resting state scan leading to 18 correlation maps for 3 experimental trials performed on each animal. Subsequently all correlation maps were averaged across trials and animals in each group. A Fisher z-transformation was used to convert the correlation coefficients to z-scores before averaging. After averaging, an inverse transform was subsequently used to obtain voxel-wise average correlation coefficient values in the group RSFC maps. 
For group statistical comparisons, 3D anatomical images were used to generate a non-linear transform from each animal subject's native space to a common space, consisting of an averaged brain from 8 sham animals obtained from our earlier analysis of sham animals 13 average sham brain using the rat brain atlas, 25 and used across each co-registered individual brain (Supplementary Figure S1 ). Similar to our earlier analyses of the sham and untreated-TBI groups, 13 the cortical ROIs encompassed motor, somatosensory, parietal, auditory, visual, perirhinal and entorhinal areas for consistent comparisons (Supplementary Figure S1 ). For each modality, group differences were calculated using a voxel level general linear model (t distribution), with treatment as the contrast and standard deviation calculated at each voxel. Significance was defined as a threshold of p<0.05 after correcting for multiple comparisons using a random field theory approach, accounting for the cluster size of contiguous significant voxels. 27 
Results
Multimodality imaging with DTI-based fractional anisotropy (FA) and apparent diffusion coefficient (ADC) variables were used as markers of brain parenchymal changes, which is known to correlate with synaptic/axonal microstructure. fMRI-BOLD based resting state functional connectivity (RSFC) was used as a marker of neural circuit activity and transient hypercapnia-induced fMRI-BOLD as a surrogate for cerebrovascular reactivity (CVR).
Together these parameters provide a multidimensional assessment of the effects of Kaempferol treatment in improving outcomes of developmental TBI. 
Journal of Neurotrauma
In our prior studies, comparison of DTI responses between sham and TBI groups revealed a significant reduction in FA and increased ADC, spreading bilaterally and across the inter-hemispheric white matter regions such as the corpus callosum. 13 Specifically, bilateral FA decreases were observed in the somatosensory and entorhinal cortices, whereas unilateral FA decreases were prominent in the ipsilateral cingulum and internal capsule regions of interest (ROIs). 13 ADC values between sham and TBI in our previous studies increased significantly in the same ROIs, indicating increased isotropic diffusion after TBI and consistent with the decreased FA. 13 In the current study comparing Kaempferol and vehicle treatments in TBI animals, strong unilateral and bilateral increases in FA occurred after Kaempferol treatment when compared to vehicle ( Figure 1A) . As observed by the group statistical maps of vehicle vs Kaempferol, FA increases were mostly across the peri-lesional regions away from the injury epicenter ( Figure 1A ). Unilateral FA increases were observed within the ipsilateral perirhinal cortex, hippocampus, hypothalamus, thalamus and amygdala, whereas bilateral FA increases were observed across motor, somatosensory cortices, insula and caudate putamen ( Figure 1A) . FA increase with Kaempferol treatment across various anatomical regions statistically determined in Figure 1A are depicted in the supplementary Figure S2B . Significant Kaempferol-induced microstructural integrity improvement as determined by increased FA was observed in various white matter ROIs, including the corpus callosum and across both hemispheres in the cingulum and internal capsule ( Figure 1B) . ADC values decreased after
Kaempferol treatment compared to vehicle. Although ADC decreases were relatively sparse compared to FA, the group statistical maps indicated highly specific ADC decreases across ipsilateral cortical regions, hippocampus, internal capsule and bilaterally across the hypothalamus ( Figure 1C ). ADC changes determined across different white matter ROIs showed significant ADC decrease only across the corpus callosum after Kaempferol treatment when compared to vehicle ( Figure 1D ). ADC decrease after Kaempferol treatment across various anatomical regions statistically determined in Figure 1B are depicted in the supplementary Figure S2D . Taken together with our prior results of untreated TBI versus sham 13 
the perirhinal cortex, hippocampus, hypothalamus, thalamus, amygdala, and corpus callosum, but also across additional structures such as the insula and caudate putamen.
From our previous studies, all RSFC networks (somatosensory cortical, hippocampal and thalamic seed voxels) were observed to have higher bilateral symmetry in sham compared to TBI animals. A significant ipsilateral decrease in RSFC network spatial extent was observed in TBI when compared to sham. 13 In the current treatment study, all RSFC networks (somatosensory cortical, hippocampal and thalamic) showed similar ipsilateral RSFC spatial extent decrease in the vehicle-treated TBI animal group (Figures 2A,3A and 4A), and comparable to the untreated TBI group observed earlier 13 . Kaempferol's effect on RSFC was investigated by comparing the vehicle-and Kaempferol treated TBI groups across the somatosensory cortical, hippocampal and thalamic RSFC networks. A significant bilateral increase in RSFC network spatial extent occurred across the cortical and hippocampal networks (Figure 2A and 3A) , whereas no significant changes were apparent in the thalamic RSFC network ( Figure 4A ). RSFC strength in various anatomical ROIs within these RSFC networks, have been shown previously to decrease after TBI when compared to sham. 13 CVR maps, reporting on regional vasomotive functions were obtained on a voxel-wise manner basis based on fMRI-BOLD response amplitude to the CO 2 stimulus as assessed by our previous studies. 13 While sham animals had a significantly higher global CVR 
compared to untreated-TBI as assessed by our previous studies, 13 the current results assessing Kaempferol effects against TBI showed no significant effect on the CVR when compared to vehicle-treated TBI animals ( Figure 5 ). Quantitative statistical comparisons using a t-test between vehicle and Kaempferol groups, performed voxel-wise throughout the brain, did not reveal any significant clusters of altered CVR (data not shown).
Discussion
Kaempferol dose used in the present study was in the range of human dietary intake of flavonol rich foods 28 and 1000 times lower than the human safety limits of 1000 mg/Kg. 29 No significant differences were observed in mortality between vehicle and Kaempferol treated TBI animals. As a natural flavonoid compound, Kaempferol has been shown to specifically act on the mitochondrial Ca 2+ uniporter (mCU) channel by enhancing it activity in vitro, 14 and capable of crossing the blood brain barrier. 30 Low-dose acute Kaempferol treatments in vivo (ie., 1mg/Kg i.v) have demonstrated its neuroactive effects of boosting stimulusinduced neurovascular coupling, 31, 32 neuronal electrical activity and the baseline oxidative metabolism in the normal brain. 32 Studying Kaempferol's mechanism of action in vivo, comparable doses of 1mg/Kg i.p Kaempferol treatments were made during the acute/subacute window (1, 24 and 48 hours post-TBI) and assessed in vivo using the rat model of developmental TBI. 16 This early Kaempferol treatment mitigated the TBIinduced brain energy metabolic decline, improved neural viability and behavior at 72 hours post injury. 16 A metabolome-wide analysis of the brain indicated that Kaempferol's effects in the post-TBI brain was predominantly via its action on mitochondria-related biochemical pathways. 16 
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Mitochondrial heterogeneity and the hypothesis of differential treatment outcomes across brain compartments and regions.
While the in vivo treatment studies have so far established Kaempferol's mitochondrial mechanism of action, neuroactive impact in the working brain and beneficial effects in developmental TBI outcomes, 16, [31] [32] [33] its overall systemic impact within the brain can be hypothesized to vary depending on mitochondrial structural and functional heterogeneity across various cellular populations. Brain regional mitochondrial heterogeneity and its placement within the context of cellular, functional, developmental and neuroanatomical environment are crucial to interpret pediatric brain pathophysiological changes. Additionally active consideration of mitochondrial heterogeneity, which is the true in vivo scenario, may help reconcile the differential impact of mitochondrially targeted treatments across various brain compartments. 34 Hence
Kaempferol-induced mitochondrial functional changes and its consequent downstream impact on cellular pathways was hypothesized to manifest in a heterogeneous manner in a variety of cellular populations. The current multimodal imaging design with clinically relevant markers enabled testing across cellular compartments and brain regions.
Different multimodal imaging outcome results demonstrate the heterogeneous impact of mitochondrially targeted Kaempferol treatment across different cell types of the brain in vivo.
Neuronal (synaptic/non-synaptic) and astroglial mitochondrial impact 35 RSFC topology was significantly improved across the somatosensory cortical and hippocampal but not thalamic networks after Kaempferol treatments signifying a favorable outcome on the neuronal mitochondrial compartments (Figures 2,3 and 4) . Both synaptic and non-synaptic mitochondria seem to be affected as observed from the increases in FA ( Figure 1A and 1B) and somatosensory cortical RSFC network topology and strength ( Figure 2 ). Earlier studies with the same dose of Kaempferol showed improved stimulation-induced cerebral blood flow (CBF) responses, suggesting improved neural circuit activity and neurovascular coupling. 17 As astrocytes significantly enable the neurovascular coupling process, their mitochondria are likely to have been impacted 
leading to better astrocytic Ca 2+ signaling and neurovascular activity. As Ca 2+ overload occurs in the temporal window of approximately 6 hours after TBI through mitochondrial dysfunction and arrest of Ca 2+ transport, 36 the ion homeostatic benefits derived by both neuronal and astroglial mitochondria from Kaempferol treatment to improve their viability and function. However, the intensity of Kaempferol action is likely to vary depending on the functional differences of neuronal and astroglial mitochondria. Even across neurons, both synaptic and non-synaptic mitochondria may derive different Kaempferol treatment benefits with synaptic mitochondria receiving a higher impact. This possibility is due to a relatively greater TBI-induced oxidative damage of synaptic mitochondria when compared to non-synaptic. 35 Further heterogeneous effects could be observed in the thalamic RSFC network which showed no significant impact of Kaempferol (Figure 4) , contrasting the robust neural connectivity improvements within the somatosensory cortical ( Figure 2 ) and hippocampal RSFC networks (Figure 3) .
Although the thalamic region is very functionally diverse containing several nuclei with specific functions, the individual thalamic RSFC networks obtained from the six seed voxels placed randomly in different locations within the thalamic ROI has been shown to be topologically stable as demonstrated our earlier study. 26 Hence spatially separated selection of the 6 random seed voxels within all ROIs, including the thalamic ROI, was unlikely to cause any significant RSFC variability resulting in no improvement of thalamic RSFC after Kaempferol treatment. Thalamic regions also do not display neurodegeneration, but show gradual neuronal atrophy from early perisomatic axotomy after a diffuse brain injury, very similar to our current model. 37 The subsequent post-TBI reorganization of the thalamus is also complex, leading to hypersensitivity in somatosensory responses and hypothesized as a maladaptive reorganization extending into the chronic time periods after TBI. 38 A diminishing RSFC spatial extent and strength in the ipsilateral thalamic regions at adolescence corroborate prior neuronal atrophic evidence. 37 However, Kaempferol's inability to improve thalamic RSFC strength, in the current study, may point to a differently vulnerable mitochondrial population supporting a prolonged neural atrophic mechanism.
Endothelial and smooth muscle mitochondria impact 39, 40 Extracellular mitochondria after a central nervous system (CNS) injury have been proposed as a cellular rescue signal 41 , and demonstrated to improve endothelial function in vivo after a stroke. 42 Although endothelial mitochondrial properties can be expected to differ from neural mitochondria in certain specific functions, they would generally benefit from Kaempferol treatment since the mitochondrial Ca 2+ uniporter channel (mCU), which is the target for Kaempferol is expressed in all mitochondrial types. While it is not known if mCU densities varied across various distinct cellular mitochondria within the CNS, observed to persist through development in the current model of TBI. 17 Kaemferol treatment, although helpful in improving behavioral and brain responses, had no effect on the decreased baseline CBF perfusion observed ipsilateral to the TBI. 17 Decreased CBF is a hallmark of concussive TBI in humans. 45 and its acute vascular origins and cellular mechanisms have been well studied in preclinical animal models of TBI of various severity. 46 While chronic vascular rearrangement continues beyond 6 months after TBI with significant vessel proliferation in both the lesional and perilesional regions, there are no direct correlation between CBF and regenerated vessel density. 47 Furthermore, prolonged inflammation, BBB disruption and white matter damage may sustain chronic microvascular dysfunctions after TBI. 48 Recent studies indicate impaired myogenic constriction of cerebral arteries through mitochondrial oxidative stress after a TBI, which was restored by mitoTEMPO, a mitochondria-targeted antioxidant. 49 Hence TBI-induced mitochondrial 
responses maybe very different in vascular cells, necessitating entirely different doses of Kaempferol for optimal effects. Higher doses of Kaempferol is known to induce significant antioxidative and anti-inflammatory responses. Hence, future dose escalation studies may help determine possibilities of cerebrovascular protection through mitochondrially triggered redox-and immuno-modulations.
To determine vehicle effects within the brain, untreated and vehicle-treated TBI animal comparisons were made in our earlier study, which showed no significant vehicleinduced effects on the brain metabolome. 2 Hence vehicle treated sham group was not considered in the current study. Furthermore, given Kaempferol's properties as a dietary flavonol compound with proven safety in humans, 28 it is highly unlikely that Kaempferol may have significant effects on the structural or functional components within the normal working brain. Hence the absence of a Kaempferol-treated sham group in the current study, although a moderate weakness, is very unlikely to alter the overall conclusion of the study.
Conclusion
As TBI pathology is broad, its prognosis and treatment outcomes can be best understood multi-dimensionally using a systems approach spanning the genomic, proteomic, metabolomic, tissue, organ and organism levels. 50 The demonstrated multimodal translational imaging of TBI treatment and its ability to distinguish mitochondrial treatment responses across various tissue compartments and regions indicates its critical value within this futuristic systems framework. While the Kaempferol dose used in the current preclinical trial favorably impacted neural populations, a lack of cerebrovascular improvement and minimal neural impact in the thalamic region indicated mitochondrial functional diversity. The current results justify future Kaempferol dose/treatment window optimizations extending to cerebrovascular protection, with potential to further enhance the improved behavioral and brain responses after TBI.
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